Top

Published in:

01-09-2019 | Disease Modifying Anti-Rheumatic Drug | Recommendations

Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis

Authors: Hebah Alhajeri, Fatemah Abutiban, Wasl Al-Adsani, Adel Al-Awadhi, Ali Aldei, Ahmad AlEnizi, Naser Alhadhood, Adeeba Al-Herz, Waleed Alkandari, Ahmad Dehrab, Aqeel A. Muhanna Ghanem, Eman Hasan, Sawsan Hayat, Khulood Saleh, Hoda Tarakmeh, Yaser Ali

Published in: Rheumatology International | Issue 9/2019

Abstract

The Kuwait Association of Rheumatology (KAR) aimed to develop a set of recommendations for the treatment of patients with rheumatoid arthritis (RA), tailored to the unique patient population and healthcare system of Kuwait. Each recommendation was developed based on expert opinion and evaluation of clinical practice guidelines from other international and national rheumatology societies. Online surveys were conducted to collate feedback on each KAR member’s level of agreement (LoA) with definitions of disease-/treatment-related terms used and the draft recommendations. Definitions/recommendations achieving a pre-defined cut-off value of ≥ 70% agreement were accepted for inclusion. Remaining statements were discussed and revised at a face-to-face meeting, with further modifications until consensus was reached. A final online survey was used to collect feedback on each KAR member’s LoA with the final set of recommendation statements on a scale of 0 (complete disagreement) to 10 (complete agreement). Group consensus was achieved on 66 recommendation statements, including 3 overarching principles addressing the pharmacological treatment and management of RA. Recommendations focused on treatment of early RA, established RA, patients with high-risk comorbidities, women during pregnancy and breastfeeding, and screening and treatment of opportunistic infections. The KAR 2018 Treatment Recommendations for RA reported here are based on a synthesis of other national/international guidelines, supporting literature, and expert consensus considering the Kuwaiti healthcare system and RA patient population. These recommendations aim to inform the clinical decisions of rheumatologists treating patients in Kuwait, and to promote best practices, enhance alignment and improve the treatment experience for patients.

Available only for authorised users

Gibofsky A (2012) Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 18(13 Suppl):S295–S302PubMed

Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316–1322. https://doi.org/10.1136/annrheumdis-2013-204627 CrossRef

Al-Herz A, Al-Awadhi A, Saleh K, Al-Kandari W, Hasan E, Ghanem A et al (2016) A comparison of rheumatoid arthritis patients in Kuwait with other populations: results from the KRRD registry. Br J Med Med Res 14:1–11. https://doi.org/10.9734/BJMMR/2016/24673 CrossRef

van Vilsteren M, Boot CRL, Knol DL, van Schaardenburg D, Voskuyl AE, Steenbeek R et al (2015) Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord 16:107. https://doi.org/10.1186/s12891-015-0562-x CrossRefPubMedPubMedCentral

Gerhold K, Richter A, Schneider M, Bergerhausen H-J, Demary W, Liebhaber A et al (2015) Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology 54(10):1858–1866. https://doi.org/10.1093/rheumatology/kev194 CrossRefPubMed

Finckh A, Liang MH, van Herckenrode CM, de Pablo P (2006) Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55(6):864–872. https://doi.org/10.1002/art.22353 CrossRef

Goekoop-Ruiterman YM, de Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406–415. https://doi.org/10.7326/0003-4819-146-6-200703200-00005 CrossRefPubMed

Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360–1372. https://doi.org/10.1001/jama.2018.13103 CrossRefPubMed

Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I et al (2002) Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 41(12):1346–1356. https://doi.org/10.1093/rheumatology/41.12.1346 CrossRefPubMed

10.

Combe B, Lula S, Boone C, Durez P (2018) Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol 36(4):658–667PubMed

11.

Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R (2014) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73(1):3–5. https://doi.org/10.1136/annrheumdis-2013-204317 CrossRefPubMed

12.

Rein P, Mueller RB (2017) Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther 4(2):247–261. https://doi.org/10.1007/s40744-017-0073-3 CrossRefPubMedPubMedCentral

13.

Cohen S, Kay J (2017) Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol 29(3):260–268. https://doi.org/10.1097/bor.0000000000000379 CrossRefPubMed

14.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 Update of the 2008 American College of Rheumatology (ACR) recommendations for the use of disease-modifying anti-rheumatic drugs and biologics in the treatment of rheumatoid arthritis (RA). Arthritis Care Res 64(5):625–639. https://doi.org/10.1002/acr.21641 CrossRef

15.

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26. https://doi.org/10.1002/art.39480 CrossRefPubMed

16.

Combe B, Landewé R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM et al (2017) 2016 Update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76(6):948–959. https://doi.org/10.1136/annrheumdis-2016-210602 CrossRefPubMed

17.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977. https://doi.org/10.1136/annrheumdis-2016-210715 CrossRef

18.

Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810. https://doi.org/10.1136/annrheumdis-2015-208840 CrossRefPubMed

19.

Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B et al (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39(8):1559–1582. https://doi.org/10.3899/jrheum.110207 CrossRefPubMed

20.

Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM et al (2015) APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 18(7):685–713. https://doi.org/10.1111/1756-185x.12754 CrossRefPubMed

21.

Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693–1697. https://doi.org/10.1093/rheumatology/kev404 CrossRefPubMed

22.

World Population Review (2018) Kuwait population 2018. https://Worldpopulationreview.Com/Countries/Kuwait-Population/. Accessed 10 Jan 2019

23.

The Public Authority for Civil Information (2015) Kuwait stat app for statistical services. Statistical Services System. https://www.paci.gov.kw/stat/default.aspx. Accessed 23 Oct 2018

24.

World Health Organization (2018) Global tuberculosis report 2018. https://www.who.int/tb/publications/global_report/en/. Accessed 23 Oct 2018

25.

Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 30(3):194–210CrossRef

26.

de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA et al (2012) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78. https://doi.org/10.1136/annrheumdis-2011-201162 CrossRefPubMed

27.

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F (2011) Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review literature. Int J Rheumatol 2011:845496. https://doi.org/10.1155/2011/845496 CrossRefPubMedPubMedCentral

28.

Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE et al (2017) Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 56(5):689–697. https://doi.org/10.1093/rheumatology/kew271 CrossRefPubMed

29.

Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31(4):645–648PubMed

30.

Goodman SM, Cronstein BN, Bykerk VP (2015) Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol 33(2):272–278PubMed

31.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–62. https://doi.org/10.1136/annrheumdis-2016-210457

32.

Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP et al (2018) Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. J Rheumatol 45(1):14–21. https://doi.org/10.3899/jrheum.161161 CrossRefPubMed

33.

Burmester G-R, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL et al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised concerto trial. Ann Rheum Dis 74(6):1037–1044. https://doi.org/10.1136/annrheumdis-2013-204769 CrossRefPubMed

34.

Martinez-Feito A, Plasencia-Rodriguez C, Navarro-Compan V, Hernandez-Breijo B, Gonzalez MA, Monjo I et al (2019) The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol 38(3):949–954. https://doi.org/10.1007/s10067-018-4355-0 CrossRefPubMed

35.

Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47(4):507–513. https://doi.org/10.1093/rheumatology/ken034 CrossRefPubMed

36.

Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E et al (2016) Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 75(8):1428–1437. https://doi.org/10.1136/annrheumdis-2016-209201 CrossRefPubMed

37.

van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60(8):2262–2271. https://doi.org/10.1002/art.24661 CrossRefPubMed

38.

Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 68(1):25–32. https://doi.org/10.1136/ard.2007.083188 CrossRefPubMed

39.

Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol 68(1):56–66. https://doi.org/10.1002/art.39399 CrossRefPubMed

40.

Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH (2013) The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 62(11):1523–1528. https://doi.org/10.1136/gutjnl-2013-305300 CrossRefPubMed

41.

Laharie D (2014) Previous cancer and/or lymphoma in patients with refractory IBD–Pro: anti-TNF or immunosuppressive treatment. Dig Dis (Basel, Switzerland) 32(Suppl 1):116–21. https://doi.org/10.1159/000367861 CrossRef

42.

Mantzaris GJ (2014) Previous cancer and/or lymphoma in patients with refractory IBD–Con: anti-TNF or conventional immunosuppressive treatment. Digestive Diseases (Basel, Switzerland) 32(Suppl 1):122–127. https://doi.org/10.1159/000367862 CrossRef

43.

Elandt K, Aletaha D (2011) Treating rheumatic patients with a malignancy. Arthritis Res Ther 13(3):223. https://doi.org/10.1186/ar3352 CrossRefPubMedPubMedCentral

44.

Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B et al (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: Part II Safety. J Rheumatol 39(8):1583–1602. https://doi.org/10.3899/jrheum.120165 CrossRefPubMed

45.

Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K (2010) Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection—United States, 2010. MMWR recommendations and reports: morbidity and mortality weekly report 59(RR-5):1-25

46.

Winthrop KL, Weinblatt ME, Daley CL (2012) You can’t always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you need. Ann Rheum Dis 71(11):1757–1760. https://doi.org/10.1136/annrheumdis-2012-201979 CrossRefPubMed

47.

Akhtar S, Mohammad HG (2008) Seasonality in pulmonary tuberculosis among migrant workers entering Kuwait. BMC Infect Dis 8:3. https://doi.org/10.1186/1471-2334-8-3 CrossRefPubMedPubMedCentral

48.

Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37(10):705–712. https://doi.org/10.1111/j.1445-5994.2007.01479.x CrossRefPubMed

49.

Lok ASF, Ward JW, Perrillo RP, McMahon BJ, Liang TJ (2012) Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 156(10):743–745. https://doi.org/10.1059/0003-4819-156-10-201205150-00013 CrossRefPubMedPubMedCentral

50.

Yang CH, Wu TS, Chiu CT (2007) Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 157(3):587–590. https://doi.org/10.1111/j.1365-2133.2007.08058.x CrossRefPubMed

51.

Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR et al (2015) Safety of biologic and non-biologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther 17(1):136. https://doi.org/10.1186/s13075-015-0628-z CrossRefPubMedPubMedCentral

52.

Weinbaum CM, Mast EE, Ward JW (2009) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 49(Suppl 5):S35–S44. https://doi.org/10.1002/hep.22882 CrossRefPubMed

53.

Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY et al (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70(10):1719–1725. https://doi.org/10.1136/ard.2010.148783 CrossRefPubMed

54.

Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(1):215–219. https://doi.org/10.1053/j.gastro.2014.10.039 CrossRefPubMed

55.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4):1560–1599. https://doi.org/10.1002/hep.29800 CrossRefPubMedPubMedCentral

56.

Zechini B, Pasquazzi C, Aceti A (2004) Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 16(9):891–896CrossRef

57.

Pompili M, Biolato M, Miele L, Grieco A (2013) Tumor necrosis factor-alpha inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 19(44):7867–7873. https://doi.org/10.3748/wjg.v19.i44.7867 CrossRefPubMedPubMedCentral

58.

Karadağ Ö, Kaşifoğlu T, Özer B, Kaymakoğlu S, Kuş Y, İnanç M et al (2016) Viral hepatitis screening guideline before biological drug use in rheumatic patients. Eur J Rheumatol 3(1):25–28. https://doi.org/10.5152/eurjrheum.2015.150072 CrossRefPubMed

59.

Krause ML, Amin S, Makol A (2014) Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 6(5):169–184. https://doi.org/10.1177/1759720X14551568 CrossRefPubMedPubMedCentral

60.

Choy EHS, Miceli-Richard C, González-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G et al (2019) The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol 37(4):694–670PubMed

61.

Ameen R, Sanad N, Al-Shemmari S, Siddique I, Chowdhury RI, Al-Hamdan S et al (2005) Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion 45(12):1973–1980. https://doi.org/10.1111/j.1537-2995.2005.00635.x CrossRefPubMed

62.

Al-Herz ASK, Al-Awadhi A, Al-Kandari W, Hasan E, Ghanem A, Ali Y et al (2018) Easy accessibility of biologics and its impact on disease activity and quality of life in Kuwaiti patients with rheumatoid arthritis [Abstract]. Arthritis Rheumatol 70(Suppl 9):624

63.

Norton BL, Holland DP (2012) Current management options for latent tuberculosis: a review. Infect Drug Resist 5:163–173. https://doi.org/10.2147/idr.s29180 CrossRefPubMedPubMedCentral

Title: Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis
Authors: Hebah Alhajeri
Fatemah Abutiban
Wasl Al-Adsani
Adel Al-Awadhi
Ali Aldei
Ahmad AlEnizi
Naser Alhadhood
Adeeba Al-Herz
Waleed Alkandari
Ahmad Dehrab
Aqeel A. Muhanna Ghanem
Eman Hasan
Sawsan Hayat
Khulood Saleh
Hoda Tarakmeh
Yaser Ali
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Disease Modifying Anti-Rheumatic Drug
Rheumatoid Arthritis
Published in: Rheumatology International / Issue 9/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-019-04372-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2019

Leflunomide treatment in juvenile idiopathic arthritis

Anterior uveitis in patients with spondyloarthropathies in a single US academic center: a retrospective study

Depression/anxiety symptoms in axial spondyloarthritis and psoriatic arthritis patients in Serbia: a pilot study

Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren’s syndrome

Gout is associated with elevated risk of erectile dysfunction: a systematic review and meta-analysis

Pharmacist-managed titration of urate-lowering therapy to streamline gout management

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage